Soumit Roy, an analyst from JonesTrading, maintained the Buy rating on CervoMed (CRVO – Research Report). The associated price target remains the same with $15.00.
Soumit Roy’s rating is based on the promising results from CervoMed’s recent data update on their open-label extension study in dementia with Lewy bodies. The study highlighted significant improvements in cognitive scores for patients treated with the new neflamapimod capsules compared to the old version, particularly in the CDR-SB score, which showed a statistically significant enhancement.
Furthermore, the company is on track to potentially initiate a Phase 3 study by mid-2026, following a planned meeting with the FDA in late 2025. This progression, combined with the ongoing collection of data from both the OLE study and a French study at a higher dosage, supports the optimistic outlook and the Buy rating for CervoMed’s stock.
Roy covers the Healthcare sector, focusing on stocks such as Elicio Therapeutics, Chimerix, and Precision BioSciences. According to TipRanks, Roy has an average return of -28.8% and a 15.35% success rate on recommended stocks.